Abiopharma

Other Scheme of Arrangement: EFFECTIVE DATE OF THE SCHEME

InMode to Present at Baird 2025 Global Healthcare Conference

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Organon & Co. - US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) andBILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

iTeos Therapeutics (ITOS) was removed from the list of traded instruments on NASDAQ exchange

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: iTeos Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: iTeos Therapeutics, Inc. - Common Stock. New value: iTeos Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: iTeos Therapeutics, Inc. - Common Stock.

Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPI

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST

Smith+Nephew PLC Notification